Comparative Pharmacology
Head-to-head clinical analysis: IONSYS versus TRAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IONSYS versus TRAL.
IONSYS vs TRAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IONSYS is an iontophoretic delivery system for fentanyl, a mu-opioid receptor agonist. Fentanyl binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception and emotional response.
Tralokinumab is a human monoclonal antibody that specifically binds to interleukin-13 (IL-13) and inhibits its interaction with the IL-13 receptor α1 and α2 subunits. This blockade reduces IL-13-mediated signaling, which is implicated in the pathophysiology of atopic dermatitis, including inflammation, pruritus, and skin barrier dysfunction.
Apply one 40 mcg fentanyl iontophoretic transdermal system to skin on upper arm or chest; delivers 40 mcg per dose on-demand for up to 24 hours or 80 doses, whichever is shorter. Maximum 2 doses per hour, 6 doses per application. Patient must be opioid-tolerant.
10 mg intravenously once daily
None Documented
None Documented
Clinical Note
moderateSertraline + Desmopressin
"The risk or severity of adverse effects can be increased when Sertraline is combined with Desmopressin."
Clinical Note
moderateSertraline + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Sertraline."
Clinical Note
moderateSertraline + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Sertraline."
Clinical Note
moderateSertraline + Cyclosporine
Terminal elimination half-life: 16.3 ± 9.1 hours for fentanyl released from IONSYS; accounts for prolonged release from depot and is longer than intravenous fentanyl (3-12 hours).
Terminal elimination half-life is 12–18 hours in patients with normal renal function (CrCl >90 mL/min). In moderate renal impairment (CrCl 30–59 mL/min), half-life extends to 24–36 hours. Clinical context: Dosing interval adjustment required for CrCl <60 mL/min.
Renal: approximately 90% as fentanyl metabolites (mainly norfentanyl) and less than 10% as unchanged drug; fecal: less than 10%.
Approximately 70% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion; 30% is eliminated in feces via biliary secretion. Total renal clearance accounts for 85% of systemic clearance.
Category C
Category C
Opioid Analgesic
Opioid Analgesic
"The metabolism of Cyclosporine can be decreased when combined with Sertraline."